* Athira Pharma Inc reported a quarterly adjusted loss of 75 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -87 cents. The mean expectation of five analysts for the quarter was for a loss of 71 cents per share. Wall Street expected results to range from -80 cents to -50 cents per share.
* Reported revenue was zero; analysts expected zero.
* Athira Pharma Inc's reported EPS for the quarter was a loss of 75 cents.
* The company reported a quarterly loss of $28.7 million.
* Athira Pharma Inc shares had risen by 68.2% this quarter and lost 69.1% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 16.1% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "hold"
Wall Street's median 12-month price target for Athira Pharma Inc is $0.55 This summary was machine generated from LSEG data November 8 at 09:07 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.71 -0.75 Missed
Jun. 30 2024 -0.74 -0.70 Beat
Mar. 31 2024 -0.79 -0.69 Beat
Dec. 31 2023 -0.96 -0.71 Beat
Comments